Keystone Financial Services Acquires Shares of 902 Insulet Co. (NASDAQ:PODD)

Keystone Financial Services bought a new position in Insulet Co. (NASDAQ:PODD) during the third quarter, according to its most recent Form 13F filing with the SEC. The firm bought 902 shares of the medical instruments supplier’s stock, valued at approximately $210,000.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the stock. Blue Trust Inc. grew its holdings in Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares in the last quarter. Venturi Wealth Management LLC grew its holdings in shares of Insulet by 633.3% in the third quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares during the period. International Assets Investment Management LLC acquired a new stake in Insulet during the second quarter worth about $32,000. UMB Bank n.a. raised its stake in Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock worth $37,000 after purchasing an additional 81 shares during the period. Finally, CVA Family Office LLC boosted its holdings in Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock valued at $50,000 after purchasing an additional 145 shares during the last quarter.

Insulet Price Performance

Shares of NASDAQ PODD opened at $275.70 on Tuesday. The company has a current ratio of 3.60, a quick ratio of 2.71 and a debt-to-equity ratio of 1.36. Insulet Co. has a twelve month low of $156.00 and a twelve month high of $279.40. The stock has a 50 day moving average of $233.46 and a two-hundred day moving average of $205.26. The stock has a market cap of $19.33 billion, a P/E ratio of 47.21, a P/E/G ratio of 5.00 and a beta of 1.22.

Analyst Upgrades and Downgrades

A number of research firms recently commented on PODD. Barclays upped their price objective on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday. Piper Sandler raised their price objective on Insulet from $230.00 to $285.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 17th. Canaccord Genuity Group raised their price objective on Insulet from $236.00 to $269.00 and gave the stock a “buy” rating in a research report on Wednesday, September 25th. UBS Group raised their price objective on Insulet from $211.00 to $223.00 and gave the stock a “neutral” rating in a research report on Friday, August 9th. Finally, Morgan Stanley raised their price objective on Insulet from $234.00 to $317.00 and gave the stock an “overweight” rating in a research report on Monday. Three analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, Insulet currently has an average rating of “Moderate Buy” and an average price target of $253.27.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.